3 July 2019 in The Primary Care Companion For CNS Disorders
To assess whether the eye-tracking approach of the RECOGNeyes game has potential therapeutic benefits for children with neurodevelopmental disorders, in particular attention-deficit/hyperactivity disorder (ADHD). RECOGNeyes is a computer game that is played using the eyes as the game controller. The rationale behind the game is that individuals with ADHD have an underdeveloped attention control system. This attention control system is underdeveloped not because they lack this capacity but because this ability has not been sufficiently developed. The game was designed as an intervention for training visual attention in ADHD. The sample included 28 children aged 8-15 years (18 aged < 12 y and 10 aged ≥ 12 y) previously diagnosed with ADHD (DSM-5 criteria). The participants were randomly divided into 2 groups. The experimental group played RECOGNeyes with eye-tracker for 3 weeks (3 times/week) at home, while the control group played the game using the mouse. Different attentional parameters were assessed before and after training. The study was conducted from January 2018-June 2018. Participants from the eye-tracker group showed an improvement posttest compared to pretest in impulsivity (P = .0067), reaction time (P < .0001), and fixation gaze control (P < .0001). No changes were found in mouse control between pretest and posttest assessments. RECOGNeyes is a child-friendly, interactive game combined with eye-tracking technology that seems to provide an improvement in the visual attention system, which is especially indicated for ADHD patients. This game might be used as an alternative to pharmacologic therapy and may provide new insights into the treatment of ADHD..
25 July 2023 in Molecular Psychiatry
25 July 2023 in Biomedicine & Pharmacotherapy
The endocannabinoid system is prominently implicated in the control of cocaine reinforcement due to its relevant role in synaptic plasticity and neurotransmitter modulation in the mesocorticolimbic system. The inhibition of fatty acid amide hydrolase (FAAH), and the resulting increase in anandamide and other N-acylethanolamines, represents a promising strategy for reducing drug seeking. In the present study, we aimed to assess the effects of the FAAH inhibitor URB597 (1 mg/kg) on crucial features of cocaine addictive-like behaviour in mice. Therefore, we tested the effects of URB597 on acquisition of cocaine (0.6 mg/kg/inf) self-administration, compulsive-like cocaine intake and cue-induced drug-seeking behaviour during withdrawal. URB597 reduced cocaine intake under conditioned punishment while having no impact on acquisition. This result was associated to increased cannabinoid receptor 1 gene expression in the ventral striatum and medium spiny neurons activation in the nucleus accumbens shell. Moreover, URB597 mitigated cue-induced drug-seeking behaviour during prolonged abstinence and prevented the withdrawal-induced increase in FAAH gene expression in the ventral striatum. In this case, URB597 decreased activation of medium spiny neurons in the nucleus accumbens core. Our findings evidence the prominent role of endocannabinoids in the development of cocaine addictive-like behaviours and support the potential of FAAH inhibition as a therapeutical target for the treatment of cocaine addiction.
21 January 2023 in bioRxiv
Background Patients diagnosed with fetal alcohol spectrum disorder (FASD) show persistent cognitive disabilities, including memory deficits. However, the neurobiological substrates of these deficits remain unclear. Here, we studied the participation of the expanded endocannabinoid system (ECS), which is known to be affected by alcohol in other life periods, and it is involved in memory impairments of neurodevelopmental disorders. Methods C57BL/6 female mice were exposed to a time-limited access to either water or alcohol to model prenatal and lactation alcohol exposure (PLAE). The expanded ECS was analyzed in the prefrontal cortex and the hippocampus of the offspring at post-partum day (PD) 25 and 70. Then, memory performance was tested after the repeated administration (from PD25 to PD34) of: i) URB597, to increase N-acylethanolamines (NAEs), and GW9662, a peroxisome proliferator-activated receptor gamma (PPAR-γ) antagonist; ii) pioglitazone, a PPAR-γ agonist. Finally, we used a viral approach to upregulate astrocytic PPAR-γ in the hippocampus to restore memory deficits. Results We report that PLAE causes a hippocampal reduction of NAEs and PPAR-γ at PD25. Moreover, URB597 suppresses PLAE-induced memory deficits through PPAR-γ, since its effects are prevented by GW9662. Direct PPAR-γ activation, using pioglitazone, also ameliorates memory impairments. Lastly, we demonstrate that the upregulation of PPAR-γ in hippocampal astrocytes is sufficient to rescue PLAE-induced memory deficits. Conclusion Our data reveal a bidirectional link between memory deficits and expanded ECS alterations in the context of early alcohol exposure. Furthermore, we proved that PPAR-γ in hippocampal astrocytes represents a specific therapeutic target for memory deficits in FASD.